Akira Gillingham, MD
Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1265871867
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 62.8% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $19,027, more than ten times the $722 reported in 2019. Among urogynecology and reconstructive pelvic surgery clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $180.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$36K
- Coloplast$10K
- Axonics, Inc.$2K
- AbbVie$2K
- Origami Surgical Inc$2K
- Medtronic$1K
- plus $4K from 24 others
Across 1 payment — averaging $4657.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$5K
What the payments were for
- Consulting fees$5,98010%
- Speaking & faculty fees$31,36354%
- Travel & lodging$4,2377%
- Food & beverage$8,41115%
- Education$7,82414%
- Entertainment$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 84 | $36,307 |
| Coloplast | 31 | $10,427 |
| Axonics, Inc. | 44 | $2,326 |
| AbbVie(2 entities) | 64 | $1,890 |
| Origami Surgical Inc | 1 | $1,750 |
| Medtronic(2 entities) | 28 | $1,478 |
| Boston Scientific | 11 | $1,184 |
| Escala Medical Inc. | 2 | $526 |
| Femselect Inc. | 3 | $307 |
| Carbon Medical Technologies, Inc. | 1 | $300 |
| Sumitomo Pharma America, Inc. | 11 | $213 |
| Cook Medical LLC | 4 | $197 |
| Pfizer | 10 | $158 |
| Valencia Technologies Corporation | 3 | $151 |
| Intuitive Surgical | 3 | $87 |
| Caldera Medical, Inc | 1 | $75 |
| Bluewind Medical | 1 | $67 |
| Urovant Sciences Inc | 3 | $65 |
| Avation Medical, Inc. | 3 | $57 |
| Baxter Healthcare | 2 | $50 |
| Therapeuticsmd, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Renovia Inc | 1 | $22 |
| Myovant Sciences Inc. | 1 | $22 |
| Provepharm Inc. | 1 | $21 |
| 180 Medical, Inc. | 1 | $20 |
| Astellas Pharma Global Development | 1 | $19 |
| Millicent US Inc | 1 | $17 |
| Coopersurgical, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,835 in reported general payments places this provider in the 95th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
See all urogynecology and reconstructive pelvic surgery providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 258 | $160,793 |
| MyrbetriqMirabegron | 148 | $85,968 |
| Estradiol | 89 | $5,998 |
| PremarinEstrogens, Conjugated | 11 | $4,561 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 81 | $636 |
| Solifenacin Succinate | 27 | $377 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 120 | $309 |
| Ciprofloxacin Hcl | 20 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $213 | $160,793258 claims |
| Astellas Pharma US IncMyrbetriq | $36,307 | $85,968148 claims |
| PfizerPremarin | $158 | $4,56111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.
Other urogynecology and reconstructive pelvic surgery in Chicago
- Abraham ShashouaChicago$339K
- Kimberly KentonChicago$43K
- Traci BeckChicago$32K
- Margaret MuellerChicago$26K
- Carol BretschneiderChicago$14K
- Trieu DoChicago$11K
- Sean GeorgeChicago$9K
- Thythy PhamChicago$8K
- Ankita GuptaChicago$7K
- Sarah AdelsteinChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.